Target intelligence / Profile preview

β-Glucosidase (BGL)

Target
BGL
Molecular classification
Enzyme, Glycoside hydrolase (GH) family 1, Glycoside hydrolase (GH) family 3, Glycoside hydrolase (GH) occasionally other GH families
01

Overview

β-Glucosidase is an enzyme (EC 3.2.1.21) that hydrolyzes β-D-glucosidic bonds in a variety of glycosides, oligosaccharides, and notably cellulose, releasing glucose. It is composed of polypeptide chains with conserved catalytic domains featuring a (β/α)8-barrel fold and critical glutamate residues for nucleophilic and acid/base catalysis at the active site. In nature, these enzymes are crucial for the breakdown of plant biomass, immune defense, symbiosis, and metabolism. In medicine, acid-β-glucosidase (a lysosomal variant known as glucocerebrosidase) is replaced via enzyme therapy to treat Gaucher disease. Industry uses various β-glucosidases for biofuel production, food processing, and cellulose hydrolysis. Their function and specificity depend on their glycoside hydrolase family, substrate preference, and structure, with broad variation among species.

Other names
beta-glucosidaseβ-D-glucoside glucohydrolasecellobiaseBGL
02

Mechanism of action

Substrate hydrolysis via a two-step retaining mechanism involving nucleophilic attack and acid/base catalysis by active site glutamate residues. Enzyme replacement drugs restore deficient enzyme activity in lysosomal storage disorders.

03

Biological functions

Hydrolysis of glycosides, oligosaccharides, and celluloseCatabolism of plant cell wallsParticipation in plant defense, signaling, symbiosis, and secondary metabolismDigestion of dietary oligosaccharides in animals
04

Disease associations

Lysosomal storage disease (Gaucher disease)Other metabolic disorders involving glycoside hydrolase deficienciesPotential involvement in cancer and plant pathogen interactions (due to its role in plant defense)
05

Safety considerations

Enzyme replacement therapy: infusion-related reactions, immunogenicityIndustrial usage: potential for allergenicity due to fungal sourcesProduct inhibition, low enzyme stability in industrial applications
06

Interacting drugs

Imiglucerase

1 more in the full profile.

07

Biomarkers

β-glucosidase activity levels in blood and tissues (especially for Gaucher disease diagnosis)Accumulation of glucosylceramide in lysosomal disorders

Beyond the preview

Go deeper on β-Glucosidase (BGL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on β-Glucosidase (BGL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call